The Advanced Certificate Program in
Lung Cancer Management III
  1. Curriculum III
  2. Curriculum II
  3. Curriculum I
  4. Full Course List
Co-Chairs
faculty image
Roy S. Herbst, MD, PhD
  • Professor of Medicine
  • Chief, Section of Thoracic Medical Oncology
  • Department of Thoracic/Head and Neck Medical Oncology
  • The University of Texas M.D. Anderson Cancer Center
  • Houston, Texas
    • faculty image
    Corey J. Langer, MD, FACP
  • Professor of Medicine
  • Hematology-Oncology Division
  • Department of Medicine
  • University of Pennsylvania
  • Philadelphia, Pennsylvania
    • This free yearlong CME/CE program provides clinicians with up-to-date information about the management of lung cancer, featuring an expert faculty co-chaired by Roy S. Herbst, MD, PhD, and Corey J. Langer, MD, FACP, and a comprehensive curriculum of 24 web-based courses. Get timely and practical information that you can immediately use in caring for your patients with lung cancer.
  • Assess molecular pathways, targets, histotypes, mutation status, and new staging systems for lung cancer, to improve diagnosis and associated treatment decisions that improve patient outcomes.
  • Apply knowledge of MOA, efficacy, and safety of current and emerging agents indicated for the treatment of patients with lung cancer, with consideration of meaningful endpoints, in order to optimize clinical outcomes.
  • Integrate personalized medicine methodologies to customize therapies for patients with lung cancer, based on an understanding of molecular and genetic factors associated with the disease, gender differences, never-smokers vs smoker differences, and considerations in the elderly.
    • Chemotherapy—including paclitaxel, pralatrexate, and talotrexin
    • Chemoradiation
    • Neoadjuvant & adjuvant chemotherapy
    • Consolidative chemotherapy
    • Targeted therapies: gefitinib, erlotinib, bevacizumab, sunitinib, sorafenib, lonafarnib, vandetanib, cetuximab
    • Personalized therapy
    • Maintenance therapy
    • NCCN Treatment Guidelines
    • Risk factors and risk assessment
    • Screening and early detection
    • Diagnosis
    • Staging—using TNM classification of malignant tumors in NSCLC; using limited stage and extensive stages in SCLC
    • Bronchioloalveolar carcinoma
    • PCI in lung cancer

    Target Audience

    This series of activities is designed for oncologists and other clinicians who specialize in and care for patients with lung cancer.

     

    Activity Goal

    The goal of these CME/CE activities is to examine current and emerging strategies for treating and managing patients with lung cancer.